Tag: Cancer: Leukemia
AACR: Longer Survival With Gilteritinib in FLT3mut+ AML
Longer overall survival, better remission rates seen for patients receiving gilteritinib versus salvage chemo
Favorable Outcomes Seen in Long Term for ALLR3 Trial
Findings for risk-stratified tx in B-cell precursor acute lymphoblastic leukemia, late bone marrow relapse
Only About Half of Elderly Newly Diagnosed With ALL Receive Tx
53.5 percent receive treatment within 90 days; 32.4 percent receive chemo without tyrosine kinase inhibitors
Genetic Variant Tied to Leukemia Risk in Hispanic Children
Novel susceptibility locus identified in the ERG gene for acute lymphoblastic leukemia
Obesity Linked to Adverse Events in Children With Leukemia
Obesity ups risk for treatment-requiring hypertension, insulin-requiring hyperglycemia
Addition of BMT Not Indicated in Some With Peds Hypodiploid ALL
Bone marrow transplant not beneficial if no minimal residual dz after remission induction tx
Myelodysplastic Syndrome/AML Risk Increased After Chemo
Since 2000, risks for therapy-related myelodysplastic syndrome, AML up after chemo for solid cancers
American Society of Hematology, Dec. 1-4
The 60th American Society of Hematology Annual Meeting and Exposition The annual meeting of the American Society of Hematology was held from Dec....
ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL
Improved progression-free survival with ibrutinib for older adults with untreated CLL
FDA Approves Treatment for AML Patients With Gene Mutation
Expanded approval also granted to mutation assay used to detect FLT3 mutation in AML patients
